Treating patients with type 2 diabetes: What is after lifestyle management and metformin? A focus on the glucagon-like peptide-1 receptor agonists

Journal of Family Practice

Volumn 58, Issue 9 SUPPL., 2009, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; INSULIN; LIPID; METFORMIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ALGORITHM; BLOOD PRESSURE; BODY WEIGHT; EDITORIAL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SAFETY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 2; FAMILY PRACTICE; FEMALE; HUMANS; LIFE STYLE; MALE; METFORMIN; PROGNOSIS; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 70349124956     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. American Diabetes Association. Total prevalence of diabetes & pre-diabetes. www.diabetes.org/diabetes-statistics/prevalence.jsp. Accessed July 17, 2009.
2. McWilliams JM, Meara E, Zaslavsky AM, et al. Differences in control of cardiovascular disease and diabetes by race, ethnicity, and education: US trends from 1999 to 2006 and effects of Medicare coverage. Ann Intern Med. 2009;150:505-515.
3. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006;8:419-428. (Pubitemid 44349234)
4. Vilsboll T, Zdravkovic M, Le Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-1610. (Pubitemid 46871185)
5. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592-598.
6. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
7. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635. (Pubitemid 39441462)
8. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
9. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643. (Pubitemid 44912191)
10. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.